Evicenter
MarkdownMedical informationP&T meetings
Lysergide (DT120)

Generalized anxiety disorder

Also known as MM120
Launch
Not announced
Last updated
199 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionEpidemiology

Incidence of Generalized anxiety disorder

7 evidence topics · 5 sources

Age at onset: meta-analysis of 192 epidemiological studies
MeasureGeneralised anxiety disorder
No of samples“24”View highlighted excerpt for this quote
Peak age at onset (years)“15.5”View highlighted excerpt for this quote
Proportion onset by 14 years“8.6%”View highlighted excerpt for this quote
Proportion onset by 18 years“20.4%”View highlighted excerpt for this quote
Proportion onset by 25 years“33.0%”View highlighted excerpt for this quote
25th percentile age at onset (years)“20”View highlighted excerpt for this quote
Median age at onset (years)“32”View highlighted excerpt for this quote
75th percentile age at onset (years)“42”View highlighted excerpt for this quote
High-income North America incidence of anxiety disorders (all types combined): Global Burden of Disease Study 2019
RegionIncident cases in 2019, millions (95% UI)Age-standardised incidence rate per 1000 in 2019 (95% UI)
High-income North America“2.86 (2.31, 3.52)”View highlighted excerpt for this quote“8.06 (6.44, 9.87)”View highlighted excerpt for this quote